查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859303

青蒿素聯合治療市場報告：趨勢、預測和競爭分析（至2031年）

Artemisinin Combination Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

由於醫院和診所市場的巨大機遇，全球青蒿素聯合治療市場前景廣闊。預計2025年至2031年，全球青蒿素聯合治療市場將以8.2%的複合年成長率成長。該市場的主要促進因素是其已被證實能夠快速清除寄生蟲血症、緩解症狀、提高治療成功率並預防抗藥性瘧原蟲株的出現。

  • Lucintel 預測，按類型分類，由於蒿甲醚加苯芴醇在治療併發症瘧疾方面具有卓越的療效和安全性，預計在預測期內將實現最高成長。
  • 從應用角度來看，診所預計將呈現高速成長，因為治療通常在診所進行，尤其是在瘧疾流行地區。
  • 按地區分類，由於輸入性瘧疾病例數量不斷增加以及對有效治療方案的需求，預計北美在預測期內仍將是最大的地區。

青蒿素聯合治療市場的新趨勢

由於技術、監管和研發等方面的許多發展，青蒿素聯合治療市場正在迅速轉型。這些趨勢反映了瘧疾控制領域不斷演變的挑戰，例如抗藥性和定價問題，同時也凸顯了治療領域創新和成長的機會。以下新興趨勢正在重塑青蒿素聯合療法市場，推動其朝向更有效、更容易取得和永續的解決方案：

  • 聯合療法創新：青蒿素與其他抗瘧疾藥的固定劑量複方製劑（FDC）因其使用方便、患者依從性高而日益普及。 FDC 將多種藥物組合成一片藥片，降低了抗藥性風險，並改善了治療效果。製藥公司正在研發療程更短、療效更佳的 FDC，使其在大規模瘧疾控制計畫中發揮重要作用。預計這一趨勢將推動對青蒿素類複方製劑（ACT）的需求，尤其是在瘧疾高發國家。
  • 日益重視抗藥性管理：青蒿素類藥物的抗藥性已成為一個日益嚴重的問題，研究人員正致力於開發新藥和新策略來克服這一難題。抗藥性管理方法，包括新的青蒿素類複方製劑和替代藥物，在市場上的重要性日益凸顯。這一趨勢正在影響研究方向，並推動創新藥物的研發，這些藥物能夠維持青蒿素類複方製劑的療效，尤其是在東南亞和撒哈拉以南非洲等受抗藥性瘧原蟲株影響的地區。
  • 官民合作關係：政府、國際組織和私人製藥公司之間的合作對於改善瘧疾流行地區獲得青蒿素聯合療法（ACT）的機會至關重要。官民合作關係（PPP）是確保低收入國家能夠負擔得起並獲得ACT的關鍵。此類夥伴關係正在擴大生產和分銷規模，並開發新型ACT製劑。透過公私合作，相關人員旨在擴大全球供應鏈，降低成本，並提高瘧疾流行最嚴重地區獲得ACT療法的機會。
  • 給藥機制的進步：青蒿素聯合療法（ACT）市場正在經歷藥物遞送系統的進步，旨在提高療效和患者依從性。諸如控制釋放製劑和注射用ACT等創新技術正在研究中，以提供更有效的給藥方案。預計這一趨勢將提高ACT的療效，尤其是在醫療資源匱乏或無法進行口服治療的地區。這些創新有助於克服瘧疾治療在後勤方面面臨的挑戰。
  • 整合數位健康：數位健康技術正被納入瘧疾控制項目，以改善監測、診斷和治療依從性。行動健康應用、遠端醫療和數據分析正被擴大用於即時追蹤青蒿素聯合療法（ACT）的療效。數位平台也為病患教育提供支持，並提高大眾對瘧疾預防和治療的認知。這些趨勢正在改變ACT的分發和監測格局，並加強全球應對瘧疾的行動。

青蒿素聯合治療（ACT）市場正受到一系列新興趨勢的影響，這些趨勢反映出瘧疾治療和控制領域對創新解決方案日益成長的需求。聯合藥物製劑、抗藥性管理策略以及數位醫療的整合等創新，都有助於提供更有效、更容易取得且更永續的治療方案。官民合作關係以及藥物傳遞機制的進步，進一步提升了ACT計畫在全球的推廣規模。

青蒿素聯合治療市場近期趨勢

青蒿素聯合治療（ACT）市場正經歷著顯著的發展，反映了全球瘧疾應對措施的演變。這些趨勢受到新治療方法進展、國際合作以及旨在提高ACT療效、可負擔性和可及性的監管更新的影響。以下關鍵發展闡述了ACT市場如何變革以應對當前和未來瘧疾治療的挑戰。

  • 新型青蒿素聯合療法（ACT）製劑的推出：近年來，ACT市場的發展趨勢包括推出新型製劑，這些製劑將青蒿素與吡咯萘啶和他非諾喹等新夥伴藥物相結合。這些新組合的研發旨在對抗抗藥性並提高治療效果。例如，吡咯萘啶-蒿甲醚複方製劑的推出，作為傳統ACT的替代方案，旨在解決東南亞地區青蒿素抗藥性問題。這些新型製劑有望為瘧疾治療提供更永續的解決方案。
  • 擴大非專利ACT生產：在印度、中國和其他一些國家，非專利ACT的生產正在擴大，這有助於降低瘧疾流行地區瘧疾治療的費用，並提高其可及性。對於低收入國家而言，獲得價格合理的非專利ACT對於瘧疾控制計畫的成功至關重要。這一趨勢正在促進ACT的廣泛應用，尤其是在政府衛生計畫的推動下，並減輕瘧疾治療的經濟負擔。
  • 加強全球合作與資金籌措：來自全球抗擊愛滋病、結核病和瘧疾基金（GFATM）和世界衛生組織（WHO）等組織的全球合作與籌資正在提高流行地區青蒿素類複方藥物（ACTs）的可及性。這些合作的重點是擴大ACTs的分發範圍、改善醫療衛生基礎設施以及投資瘧疾研究。加強資金籌措機制和夥伴關係在擴大撒哈拉以南非洲和其他高負擔地區ACTs的使用方面發揮關鍵作用。
  • 聚焦瘧疾消除：多個國家已承諾在2030年前消除瘧疾，而青蒿素聯合療法（ACT）是這些國家策略的核心。中國和印度等國正透過加強ACT供應鏈、提高診斷和治療率以及將ACT的使用納入更廣泛的公共衛生計劃，推進其瘧疾消除工作。這些努力正在加速低瘧疾傳播但持續存在的地區對ACT的推廣，降低瘧疾傳播率，並朝著全球消除瘧疾的目標邁進。
  • 青蒿素類複方藥物（ACT）核准監管進展：美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構近期核准了新的ACT組合和製劑。這些監管進展簡化了ACT的核准流程，使患者能夠更快地獲得創新治療方法。隨著新的組合和替代療法的核准，全球ACT市場正在走向多元化，為瘧疾治療提供了更多選擇，尤其是在面臨青蒿素抗藥性的地區。

近年來，青蒿素聯合治療（ACT）市場的發展趨勢主要集中在提高藥物療效、擴大藥物可及性以及應對抗藥性等挑戰。新型製劑的推出、學名藥的增加以及全球合作正在擴大瘧疾流行地區ACT的覆蓋範圍。瘧疾消除工作的進展和監管核准的不斷改進正在重塑市場格局，而ACT製劑的技術創新也不斷改善治療效果。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球青蒿素聯合治療市場（按類型分類）

  • 概述
  • 吸引力分析：按類型
  • 青蒿醚+苯芴醇：趨勢與預測（2019-2031）
  • 青蒿琥酯+阿莫地喹：趨勢與預測（2019-2031）
  • 青蒿素+哌喹：趨勢與預測（2019-2031）
  • 青蒿琥酯+甲氟喹：趨勢與預測（2019-2031）
  • 青蒿琥酯+磺胺多辛-乙胺嘧啶：趨勢與預測（2019-2031）
  • 吡咯萘啶-青蒿琥酯：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

5. 全球青蒿素聯合治療市場（依應用分類）

  • 概述
  • 吸引力分析：依目的
  • 醫院：趨勢與預測（2019-2031）
  • 醫療診所：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

第6章 區域分析

  • 概述
  • 全球青蒿素聯合治療市場（按地區分類）

7. 北美青蒿素聯合治療市場

  • 概述
  • 北美青蒿素聯合治療市場（按青蒿素分類）
  • 北美青蒿素聯合治療市場（按青蒿素分類）
  • 美國青蒿素聯合治療市場
  • 墨西哥青蒿素聯合治療市場
  • 加拿大青蒿素聯合治療市場

8. 歐洲青蒿素聯合治療市場

  • 概述
  • 歐洲青蒿素聯合治療市場（按類型分類）
  • 歐洲青蒿素聯合治療市場（按應用分類）
  • 德國青蒿素聯合治療市場
  • 法國青蒿素聯合治療市場
  • 西班牙青蒿素聯合治療市場
  • 義大利青蒿素聯合治療市場
  • 英國青蒿素聯合治療市場

9. 亞太地區青蒿素聯合治療市場

  • 概述
  • 亞太地區青蒿素聯合治療市場（按類型分類）
  • 亞太地區青蒿素聯合治療市場（按應用分類）
  • 日本青蒿素聯合治療市場
  • 印度青蒿素聯合治療市場
  • 中國青蒿素聯合治療市場
  • 韓國青蒿素聯合治療市場
  • 印尼青蒿素聯合治療市場

10. 世界其他地區（ROW）青蒿素聯合治療市場

  • 概述
  • ROW青蒿素聯合治療市場（按類型分類）
  • ROW青蒿素聯合治療市場按應用領域分類
  • 中東青蒿素聯合治療市場
  • 南美洲青蒿素聯合治療市場
  • 非洲青蒿素聯合治療市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 透過申請獲得發展機會
  • 全球青蒿素聯合治療市場新興趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併、協議、合作關係和合資企業

第13章：價值鏈中主要企業的概況

  • 競爭分析
  • KPC Pharmaceuticals
  • Sanofi
  • Desano Holdings
  • Mylan
  • Novartis

第14章附錄

  • 圖表清單
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global artemisinin combination therapy market looks promising with opportunities in the hospital, clinic markets. The global artemisinin combination therapy market is expected to grow with a CAGR of 8.2% from 2025 to 2031. The major drivers for this market are its demonstrated effectiveness in quickly eliminating parasitemia, alleviating symptoms enhances treatment success rates, and prevent the emergence of drug-resistant malaria strains.

  • Lucintel forecasts that, within the type category, artemether+lumefantrine is expected to witness the highest growth over the forecast period due to its superior effectiveness and safety in treating uncomplicated malaria.
  • Within the application category, clinic is expected to witness the higher growth due to treatments are commonly administered in clinics, especially in malaria-endemic regions.
  • In terms of region, North America will remain the largest region over the forecast period due to the rising number of imported malaria cases and the need for effective treatment options.

Emerging Trends in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy market is undergoing rapid transformation, driven by various technological, regulatory, and research developments. These trends reflect the evolving challenges in malaria control, such as drug resistance and affordability, while also highlighting opportunities for innovation and growth in the treatment landscape. The following emerging trends are reshaping the ACT market and pushing it toward more effective, accessible, and sustainable solutions.

  • Innovation in Fixed-Dose Combinations: Fixed-dose combinations (FDCs) of artemisinin and other antimalarial drugs are gaining momentum due to their ease of use and improved patient adherence. By combining multiple drugs into a single tablet, FDCs reduce the risk of resistance and improve treatment outcomes. Pharmaceutical companies are developing more efficient FDCs with shorter treatment durations, making them highly effective for large-scale malaria control programs. This trend is expected to drive the demand for ACTs, especially in countries with high malaria transmission.
  • Growing Focus on Resistance Management: As resistance to artemisinin-based therapies becomes a growing concern, researchers are focused on developing new drugs and strategies to overcome this issue. Resistance management initiatives, including new ACT combinations and alternative drugs, are becoming a significant part of the market landscape. This trend is shaping research directions, leading to innovative drug development that can preserve the efficacy of ACT therapies in regions affected by drug-resistant malaria strains, particularly in Southeast Asia and sub-Saharan Africa.
  • Public-Private Partnerships: The collaboration between governments, international organizations, and private pharmaceutical companies is essential to improving ACT access in malaria-endemic regions. Public-private partnerships (PPPs) are key to ensuring the affordability and availability of ACTs in low-income countries. These partnerships have led to increased production and distribution, as well as the development of novel ACT formulations. Through PPPs, stakeholders aim to increase global supply chains, reduce costs, and expand access to ACT therapies in regions most affected by malaria.
  • Advances in Delivery Mechanisms: The ACT market is witnessing advancements in drug delivery systems aimed at improving treatment efficacy and patient compliance. Innovations such as controlled-release formulations and injectable ACTs are being explored to provide more efficient dosing regimens. This trend is expected to enhance the effectiveness of ACTs, especially in areas with limited access to healthcare or where oral treatments may not be feasible. These innovations are helping to address the logistical challenges of malaria treatment delivery.
  • Digital Health Integration: Digital health technologies are being integrated into malaria control programs to improve monitoring, diagnosis, and treatment adherence. Mobile health applications, telemedicine, and data analytics are increasingly used to track the effectiveness of ACT therapies in real time. Digital platforms also support patient education, increasing awareness of malaria prevention and treatment. This trend is reshaping the landscape of ACT distribution and monitoring, enhancing the global response to malaria.

The Artemisinin Combination Therapy (ACT) market is being shaped by a series of emerging trends that reflect the increasing need for innovative solutions in malaria treatment and control. Innovations like fixed-dose combinations, resistance management strategies, and digital health integration are all contributing to more effective, accessible, and sustainable treatment options. Public-private partnerships and advances in drug delivery mechanisms further enhance the scalability of ACT programs globally.

Recent Developments in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is witnessing significant developments that reflect the evolving global response to malaria. These developments are influenced by new therapeutic advancements, international collaborations, and regulatory updates aimed at enhancing the efficacy, affordability, and accessibility of ACTs. The following key developments highlight how the ACT market is transforming to address current and future challenges in malaria treatment.

  • Introduction of Novel ACT Formulations: Recent developments in the ACT market include the introduction of novel drug formulations that combine artemisinin with new partners, such as pyronaridine and tafenoquine. These new combinations are being developed to combat drug resistance and improve treatment efficacy. For example, the introduction of pyronaridine-artesunate as an alternative to traditional ACTs addresses concerns related to artemisinin resistance in Southeast Asia. These new formulations are expected to provide more durable solutions to malaria treatment.
  • Expansion of Generic ACT Production: India, China, and several other countries have ramped up the production of generic ACTs, which are helping to make malaria treatment more affordable and accessible in endemic regions. The availability of affordable generic ACTs is critical to the success of malaria control programs in low-income countries. This trend is contributing to the wider distribution of ACTs, especially through government health programs, reducing the economic burden of malaria treatment.
  • Enhanced Global Collaboration and Funding: Global collaborations and funding from organizations such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) and the World Health Organization (WHO) have increased the availability of ACTs in endemic regions. These collaborations focus on scaling up the distribution of ACTs, improving healthcare infrastructure, and investing in malaria research. Enhanced funding mechanisms and partnerships have played a crucial role in increasing access to ACTs in sub-Saharan Africa and other high-burden regions.
  • Increased Focus on Malaria Elimination: Several countries have committed to malaria elimination by 2030, and ACT is central to these national strategies. Countries such as China and India are advancing malaria elimination efforts by strengthening ACT supply chains, improving diagnosis and treatment coverage, and integrating ACT use into broader public health programs. These efforts are accelerating the deployment of ACTs in areas with low but persistent malaria transmission, helping to reduce malaria transmission rates and move closer to the goal of global eradication.
  • Regulatory Advancements in ACT Approvals: Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) have recently approved new ACT combinations and formulations. These regulatory advancements streamline the approval process for ACTs, ensuring quicker access to innovative therapies. With increasing approval of new combinations and alternative drugs, the global market for ACTs is diversifying, offering more options for malaria treatment, especially in areas facing artemisinin resistance.

Recent developments in the Artemisinin Combination Therapy (ACT) market are focused on enhancing drug efficacy, accessibility, and addressing challenges like drug resistance. The introduction of novel formulations, increased generic production, and global collaborations has expanded the availability of ACTs in malaria-endemic regions. Efforts toward malaria eradication and advancements in regulatory approvals are reshaping the market, while innovations in ACT formulations are improving treatment outcomes.

Strategic Growth Opportunities in the Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy (ACT) market is poised for growth, driven by strategic opportunities across various applications. These growth opportunities are linked to innovations in drug formulations, global health initiatives, and the expanding focus on malaria eradication. The following are key growth opportunities by application in the ACT market, each playing a critical role in shaping the future of malaria control and treatment.

  • Strengthening Malaria Control Programs: A significant growth opportunity lies in strengthening national malaria control programs (NMCPs) in malaria-endemic countries. ACTs play a central role in these programs, where governments are investing in mass drug administration campaigns, integrated vector management, and surveillance systems. Expanding access to ACTs through government-run distribution programs is critical to achieving the World Health Organization's global malaria targets, particularly in regions such as sub-Saharan Africa.
  • Pediatric Malaria Treatment: Pediatric malaria treatment represents a key growth opportunity, with increasing focus on formulating ACTs that are more suitable for children. Efforts are being made to improve the palatability, dosage, and safety of ACTs for pediatric patients, as this group faces higher mortality rates from malaria. The development of pediatric-friendly ACT formulations and combination therapies is expected to drive market growth in countries with high childhood malaria burden.
  • Scaling Up Preventative Malaria Treatment: Preventative malaria treatment strategies, such as seasonal malaria chemoprevention (SMC), are gaining momentum. ACTs are integral to these efforts, which involve administering ACTs to individuals in malaria-endemic regions during peak transmission seasons. The scalability of these preventive programs offers significant growth potential for the ACT market, especially in areas where seasonal malaria transmission is a major concern.
  • Investment in Malaria Vaccine Programs: While vaccines are not yet a complete solution, their integration with ACT treatments presents a unique growth opportunity. Malaria vaccine initiatives, such as the RTS,S/AS01 vaccine, are complementing ACTs in regions with high malaria transmission. The convergence of vaccines and ACTs creates synergies that could improve malaria control, expanding the market for ACTs and providing new channels for distribution and application.
  • Expansion of Malaria Research and Development: The ongoing research into drug-resistant malaria and new therapies presents an opportunity for growth. Investment in R&D for novel ACTs, combination therapies, and alternative treatment regimens is expected to open new market avenues. As new formulations and treatments are developed, these will complement the current ACT landscape and further drive demand.

These applications collectively contribute to a comprehensive approach to malaria control, opening up avenues for growth and reinforcing global efforts to combat malaria. As these opportunities are harnessed, the ACT market is set to become a central pillar of malaria eradication initiatives.

Artemisinin Combination Therapy Market Driver and Challenges

The Artemisinin Combination Therapy (ACT) market is influenced by various drivers and challenges. These include technological advancements in drug development, economic considerations, and regulatory frameworks. On the one hand, advancements in ACT formulations and collaborations in global health have led to increased market demand. On the other hand, challenges like drug resistance and affordability constraints affect its growth potential. Understanding these dynamics is essential to navigating the market's evolution.

The factors responsible for driving the Artemisinin Combination Therapy market include:

1. Increase in Malaria Cases: The rising incidence of malaria, particularly in sub-Saharan Africa and Southeast Asia, drives the demand for ACTs. With approximately 200 million cases globally, ACTs are critical for controlling outbreaks and improving public health outcomes. The growth in malaria cases in certain regions underscores the need for effective treatment options, supporting the market for ACTs.

2. Government and NGO Support: Governments and international organizations play a pivotal role in funding ACT distribution programs. Agencies like the Global Fund, WHO, and various national health ministries are investing heavily in malaria eradication, increasing the accessibility and availability of ACTs worldwide. This financial and institutional support fosters market expansion, especially in high-burden regions.

3. Advancements in ACT Formulations: Research and development into novel ACT formulations, such as fixed-dose combinations and improved drug delivery mechanisms, are significant drivers. These innovations improve treatment outcomes, reduce side effects, and enhance patient compliance, which makes ACTs more attractive for malaria-endemic countries, boosting market demand.

4. Cost Reduction and Generic Production: The growing production of generic ACTs, particularly by Indian and Chinese pharmaceutical companies, has lowered the cost of malaria treatment. These affordable options are critical for low-income countries, increasing the penetration of ACTs in endemic regions and driving overall market growth.

5. Focus on Malaria Eradication: The global push towards malaria elimination by 2030 provides a strong growth driver for the ACT market. National strategies focused on malaria eradication rely heavily on effective treatment options, with ACTs playing a central role. This focus on eradication ensures sustained demand and strategic investments in the ACT market.

Challenges in the Artemisinin Combination Therapy market are:

1. Drug Resistance: Artemisinin resistance, particularly in Southeast Asia, poses a significant threat to the efficacy of ACTs. The emergence of resistant strains necessitates the development of new ACT combinations and alternatives to maintain effectiveness. Resistance challenges may hinder the widespread use of current ACTs if not addressed.

2. Affordability and Access: While generics have lowered prices, the affordability of ACTs remains a challenge in low-income regions. Issues related to distribution, healthcare infrastructure, and financial barriers affect access to ACTs in the most vulnerable populations, limiting their impact on malaria control.

3. Supply Chain and Distribution Constraints: The global supply chain for ACTs faces logistical challenges, including the timely delivery of drugs to remote and hard-to-reach areas. Inefficient distribution systems and stock outs continue to be barriers, hindering the consistent availability of ACTs when and where they are most needed.

The drivers and challenges in the ACT market are interrelated. While increasing malaria cases and advancements in drug formulations fuel growth, challenges such as resistance and access barriers require attention. Strategic investments and collaborations will be crucial to overcoming these hurdles and ensuring the continued success of ACTs in global malaria control efforts.

List of Artemisinin Combination Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies artemisinin combination therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the artemisinin combination therapy companies profiled in this report include-

  • KPC Pharmaceuticals
  • Sanofi
  • Desano Holdings
  • Mylan
  • Novartis

Artemisinin Combination Therapy Market by Segment

The study includes a forecast for the global artemisinin combination therapy market by type, application, and region.

Artemisinin Combination Therapy Market by Type [Value from 2019 to 2031]:

  • Artemether+Lumefantrine
  • Artesunate+Amodiaquine
  • Dihydroartemisinin+Piperaquine
  • Artesunate+Mefloquine
  • Artesunate+Sulfadoxine-Pyrimethamine
  • Pyronaridine-Artesunate
  • Others

Artemisinin Combination Therapy Market by Application [Value from 2019 to 2031]:

  • Hospital
  • Clinic
  • Other

Artemisinin Combination Therapy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Artemisinin Combination Therapy Market

Artemisinin Combination Therapy (ACT) is the gold-standard treatment for malaria, especially in areas with widespread drug-resistant malaria strains. The market for ACT is growing due to rising malaria incidences, particularly in developing countries, but also due to advancements in drug formulations and production methods. Emerging markets, such as China and India, play a critical role in shaping this growth. Meanwhile, developed countries like the United States, Germany, and Japan are focused on supporting global health initiatives and investing in innovative ACT research. Here we explore the key developments, trends, growth opportunities, and challenges in the ACT market in the United States, China, Germany, India, and Japan.

  • United States: The United States has seen a continued focus on supporting global malaria eradication efforts. A key development in the ACT market is the government's investment in research and development of new drug formulations. The U.S. is also a major supplier of ACT medicines through organizations like the U.S. Agency for International Development (USAID). However, domestically, malaria cases are relatively low, so ACT demand is mainly driven by U.S.-funded international programs. The U.S. is increasingly involved in the deployment of newer ACT formulations in sub-Saharan Africa and Southeast Asia, with an emphasis on cost-effective and efficient therapies.
  • China: China remains a critical player in the global ACT market. The country has significantly reduced its malaria burden, but it continues to invest heavily in malaria research. China's advancements in manufacturing and producing artemisinin-based therapies have led to cost reductions, making ACT more accessible across Southeast Asia and sub-Saharan Africa. In addition, Chinese companies are increasingly involved in clinical trials to develop next-generation ACT treatments. The government is also focusing on integrating ACT with other public health programs to eradicate malaria by 2030, positioning China as a key hub for innovation and supply in the ACT market.
  • Germany: Germany's role in the ACT market is largely driven by its commitment to international development and malaria eradication. The country supports the global roll-out of ACT through collaborations with international organizations, including the World Health Organization (WHO). German pharmaceutical companies are also active in improving the efficacy and affordability of ACT, with investments in the development of fixed-dose combination therapies (FDCs). Furthermore, Germany is a key player in malaria research, with its scientific community focusing on the development of new ACT formulations to combat emerging resistance.
  • India: India, with its large population and high malaria burden, is both a producer and a consumer of ACT. The country has focused on increasing access to ACT for its domestic population, which is critical for controlling malaria transmission. Indian pharmaceutical companies, including Cipla and Dr. Reddy's Laboratories, play a key role in producing affordable generic ACTs, which are distributed through government programs. India is also engaged in developing more efficient and robust ACT formulations to combat drug resistance, with ongoing efforts to improve drug delivery and minimize side effects in the population.
  • Japan: Japan's involvement in the ACT market is primarily through international development and research. While domestic malaria cases are extremely low, Japan is heavily invested in global malaria eradication efforts. Japan's pharmaceutical industry has made significant contributions to the ACT market through collaborations and research on more effective therapies. Moreover, Japan supports malaria control through organizations like the Japan International Cooperation Agency (JICA), which is focused on funding ACT distribution in malaria-endemic regions, particularly in Southeast Asia and Africa. Japan also plays a crucial role in improving malaria diagnostics and treatment protocols.

Features of the Global Artemisinin Combination Therapy Market

  • Market Size Estimates: Artemisinin combination therapy market size estimation in terms of value ($M).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Artemisinin combination therapy market size by type, application, and region in terms of value ($M).
  • Regional Analysis: Artemisinin combination therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the artemisinin combination therapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the artemisinin combination therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the artemisinin combination therapy market by type (artemether+lumefantrine, artesunate+amodiaquine, dihydroartemisinin+piperaquine, artesunate+mefloquine, artesunate+sulfadoxine-pyrimethamine, pyronaridine-artesunate, and others), application (hospital, clinic, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Artemisinin Combination Therapy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Artemether+Lumefantrine: Trends and Forecast (2019-2031)
  • 4.4 Artesunate+Amodiaquine: Trends and Forecast (2019-2031)
  • 4.5 Dihydroartemisinin+Piperaquine: Trends and Forecast (2019-2031)
  • 4.6 Artesunate+Mefloquine: Trends and Forecast (2019-2031)
  • 4.7 Artesunate+Sulfadoxine-Pyrimethamine: Trends and Forecast (2019-2031)
  • 4.8 Pyronaridine-Artesunate: Trends and Forecast (2019-2031)
  • 4.9 Others: Trends and Forecast (2019-2031)

5. Global Artemisinin Combination Therapy Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospital: Trends and Forecast (2019-2031)
  • 5.4 Clinic: Trends and Forecast (2019-2031)
  • 5.5 Other: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Artemisinin Combination Therapy Market by Region

7. North American Artemisinin Combination Therapy Market

  • 7.1 Overview
  • 7.2 North American Artemisinin Combination Therapy Market by Type
  • 7.3 North American Artemisinin Combination Therapy Market by Application
  • 7.4 United States Artemisinin Combination Therapy Market
  • 7.5 Mexican Artemisinin Combination Therapy Market
  • 7.6 Canadian Artemisinin Combination Therapy Market

8. European Artemisinin Combination Therapy Market

  • 8.1 Overview
  • 8.2 European Artemisinin Combination Therapy Market by Type
  • 8.3 European Artemisinin Combination Therapy Market by Application
  • 8.4 German Artemisinin Combination Therapy Market
  • 8.5 French Artemisinin Combination Therapy Market
  • 8.6 Spanish Artemisinin Combination Therapy Market
  • 8.7 Italian Artemisinin Combination Therapy Market
  • 8.8 United Kingdom Artemisinin Combination Therapy Market

9. APAC Artemisinin Combination Therapy Market

  • 9.1 Overview
  • 9.2 APAC Artemisinin Combination Therapy Market by Type
  • 9.3 APAC Artemisinin Combination Therapy Market by Application
  • 9.4 Japanese Artemisinin Combination Therapy Market
  • 9.5 Indian Artemisinin Combination Therapy Market
  • 9.6 Chinese Artemisinin Combination Therapy Market
  • 9.7 South Korean Artemisinin Combination Therapy Market
  • 9.8 Indonesian Artemisinin Combination Therapy Market

10. ROW Artemisinin Combination Therapy Market

  • 10.1 Overview
  • 10.2 ROW Artemisinin Combination Therapy Market by Type
  • 10.3 ROW Artemisinin Combination Therapy Market by Application
  • 10.4 Middle Eastern Artemisinin Combination Therapy Market
  • 10.5 South American Artemisinin Combination Therapy Market
  • 10.6 African Artemisinin Combination Therapy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Artemisinin Combination Therapy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 KPC Pharmaceuticals
    • Company Overview
    • Artemisinin Combination Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Sanofi
    • Company Overview
    • Artemisinin Combination Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Desano Holdings
    • Company Overview
    • Artemisinin Combination Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Mylan
    • Company Overview
    • Artemisinin Combination Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Novartis
    • Company Overview
    • Artemisinin Combination Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Artemisinin Combination Therapy Market
  • Figure 2.1: Usage of Artemisinin Combination Therapy Market
  • Figure 2.2: Classification of the Global Artemisinin Combination Therapy Market
  • Figure 2.3: Supply Chain of the Global Artemisinin Combination Therapy Market
  • Figure 3.1: Driver and Challenges of the Artemisinin Combination Therapy Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Artemisinin Combination Therapy Market ($B) by Type
  • Figure 4.3: Forecast for the Global Artemisinin Combination Therapy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Artemether+Lumefantrine in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Artesunate+Amodiaquine in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Dihydroartemisinin+Piperaquine in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Artesunate+Mefloquine in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 4.8: Trends and Forecast for Artesunate+Sulfadoxine-Pyrimethamine in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 4.9: Trends and Forecast for Pyronaridine-Artesunate in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 4.10: Trends and Forecast for Others in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 5.1: Global Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Artemisinin Combination Therapy Market ($B) by Application
  • Figure 5.3: Forecast for the Global Artemisinin Combination Therapy Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospital in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Clinic in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Other in the Global Artemisinin Combination Therapy Market (2019-2031)
  • Figure 6.1: Trends of the Global Artemisinin Combination Therapy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Artemisinin Combination Therapy Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
  • Figure 7.3: Forecast for the North American Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
  • Figure 7.4: North American Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
  • Figure 7.6: Forecast for the North American Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 8.1: European Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
  • Figure 8.3: Forecast for the European Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
  • Figure 8.4: European Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
  • Figure 8.6: Forecast for the European Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 9.1: APAC Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
  • Figure 9.3: Forecast for the APAC Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
  • Figure 9.4: APAC Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
  • Figure 9.6: Forecast for the APAC Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 10.1: ROW Artemisinin Combination Therapy Market by Type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Artemisinin Combination Therapy Market ($B) by Type (2019-2024)
  • Figure 10.3: Forecast for the ROW Artemisinin Combination Therapy Market ($B) by Type (2025-2031)
  • Figure 10.4: ROW Artemisinin Combination Therapy Market by Application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Artemisinin Combination Therapy Market ($B) by Application (2019-2024)
  • Figure 10.6: Forecast for the ROW Artemisinin Combination Therapy Market ($B) by Application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Artemisinin Combination Therapy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Artemisinin Combination Therapy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Artemisinin Combination Therapy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Artemisinin Combination Therapy Market by Type
  • Figure 12.2: Growth Opportunities for the Global Artemisinin Combination Therapy Market by Application
  • Figure 12.3: Growth Opportunities for the Global Artemisinin Combination Therapy Market by Region
  • Figure 12.4: Emerging Trends in the Global Artemisinin Combination Therapy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Artemisinin Combination Therapy Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Artemisinin Combination Therapy Market by Region
  • Table 1.3: Global Artemisinin Combination Therapy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 3.2: Forecast for the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Artemisinin Combination Therapy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.4: Trends of Artemether+Lumefantrine in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.5: Forecast for Artemether+Lumefantrine in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.6: Trends of Artesunate+Amodiaquine in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.7: Forecast for Artesunate+Amodiaquine in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.8: Trends of Dihydroartemisinin+Piperaquine in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.9: Forecast for Dihydroartemisinin+Piperaquine in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.10: Trends of Artesunate+Mefloquine in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.11: Forecast for Artesunate+Mefloquine in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.12: Trends of Artesunate+Sulfadoxine-Pyrimethamine in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.13: Forecast for Artesunate+Sulfadoxine-Pyrimethamine in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.14: Trends of Pyronaridine-Artesunate in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.15: Forecast for Pyronaridine-Artesunate in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 4.16: Trends of Others in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 4.17: Forecast for Others in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Artemisinin Combination Therapy Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 5.4: Trends of Hospital in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 5.5: Forecast for Hospital in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 5.6: Trends of Clinic in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 5.7: Forecast for Clinic in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 5.8: Trends of Other in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 5.9: Forecast for Other in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Artemisinin Combination Therapy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Artemisinin Combination Therapy Market (2025-2031)
  • Table 7.1: Trends of the North American Artemisinin Combination Therapy Market (2019-2024)
  • Table 7.2: Forecast for the North American Artemisinin Combination Therapy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American Artemisinin Combination Therapy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American Artemisinin Combination Therapy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various application in the North American Artemisinin Combination Therapy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various application in the North American Artemisinin Combination Therapy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Artemisinin Combination Therapy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Artemisinin Combination Therapy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Artemisinin Combination Therapy Market (2019-2031)
  • Table 8.1: Trends of the European Artemisinin Combination Therapy Market (2019-2024)
  • Table 8.2: Forecast for the European Artemisinin Combination Therapy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European Artemisinin Combination Therapy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European Artemisinin Combination Therapy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various application in the European Artemisinin Combination Therapy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various application in the European Artemisinin Combination Therapy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Artemisinin Combination Therapy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Artemisinin Combination Therapy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Artemisinin Combination Therapy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Artemisinin Combination Therapy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Artemisinin Combination Therapy Market (2019-2031)
  • Table 9.1: Trends of the APAC Artemisinin Combination Therapy Market (2019-2024)
  • Table 9.2: Forecast for the APAC Artemisinin Combination Therapy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC Artemisinin Combination Therapy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC Artemisinin Combination Therapy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various application in the APAC Artemisinin Combination Therapy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various application in the APAC Artemisinin Combination Therapy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Artemisinin Combination Therapy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Artemisinin Combination Therapy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Artemisinin Combination Therapy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Artemisinin Combination Therapy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Artemisinin Combination Therapy Market (2019-2031)
  • Table 10.1: Trends of the ROW Artemisinin Combination Therapy Market (2019-2024)
  • Table 10.2: Forecast for the ROW Artemisinin Combination Therapy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW Artemisinin Combination Therapy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW Artemisinin Combination Therapy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various application in the ROW Artemisinin Combination Therapy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various application in the ROW Artemisinin Combination Therapy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Artemisinin Combination Therapy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Artemisinin Combination Therapy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Artemisinin Combination Therapy Market (2019-2031)
  • Table 11.1: Product Mapping of Artemisinin Combination Therapy Suppliers Based on Segments
  • Table 11.2: Operational Integration of Artemisinin Combination Therapy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Artemisinin Combination Therapy Revenue
  • Table 12.1: New Product Launches by Major Artemisinin Combination Therapy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Artemisinin Combination Therapy Market